SecBot SecBot
PRESS-RELEASE ·Filed Aug 18, 2026

IMTX

https://immatics.com/
MIXED
Impact 6/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Revenue miss and rising R&D spend are near-term negatives, but the Phase 3 SUPRAME trial progress and strong cash runway through 2028 support the pipeline story. Traders should focus on SUPRAME PFS topline in H1 2027 as the key catalyst; near-term volatility likely on the mixed earnings print.

DirectionMixed
Confidencehigh
Horizonweeks

Drugs in focus

IMTX drug pipeline →

IMA203

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
If Phase 3 succeeds, BLA submission is planned for 2027 with a potential commercial launch in 2027-2028.
Next catalyst
None dated

What to watchThe binary catalyst is the SUPRAME Phase 3 final PFS readout in H1 2027. Positive data would validate anzu-cel for BLA submission in 2027 and could drive significant upside toward analyst targets (~$17). A negative or underwhelming result would likely hit the stock hard given its current single-asset weighting. Interim operational updates on enrollment could come at the Q3 earnings call on Nov 16, 2026.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.09
T+0 close · Aug 18, 2026 · via day close
Latest settled
−29.37%
T+60 · $6.42
Vs SPY
−27.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $9.09entry
  2. T+1 · 3mo ago +1.76%α +1.55% · $9.25
  3. T+5 · 3mo ago +1.65%α +1.85% · $9.24
  4. T+20 · 2mo ago −2.97%α −1.98% · $8.82
  5. T+60 · 6d ago −29.37%α −27.33% · $6.42

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immatics reported Q2 2026 earnings with a narrower-than-expected net loss per share of -$0.46 (€-0.46), beating consensus EPS of -$0.48 by 9.5%, and revenue of $10.4M, below the $12.6M estimate. Key strategic updates include the SUPRAME Phase 3 trial remaining on track to complete enrollment by year-end, with topline PFS data expected H1 2027 and BLA submission in 2027, while aggregate events are occurring slower than modeled, prompting a shift to a single final analysis with enhanced OS power.

Key Financial Metrics

EPS
−$0.46
est −$0.48 · +4.2%
Revenue
$10.4M
est $12.6M · -17.5% · +92.6% YoY
Rating
in line

Key Facts

  • Q2 2026 EPS of -$0.46 beat consensus of -$0.48 by 9.5%.
  • Q2 2026 revenue of $10.4M (€9.1M) missed consensus estimate of $12.6M.
  • Net loss narrowed to $71.2M (€62.5M) from $80.1M (€70.3M) in Q2 2025.
  • Cash and equivalents stood at $448.2M (€393.4M) as of June 30, 2026, with cash reach into 2028.
  • SUPRAME Phase 3 trial enrollment on track; topline PFS data expected H1 2027, BLA submission in 2027.
  • Updated Phase 1b anzu-cel data showed 56% cORR, 14.6 months mDOR, 6.1 months mPFS, 16.2 months mOS in metastatic melanoma.
  • IMA203CD8 showed 63% ORR and 50% cORR in gynecologic cancers at ASCO 2026.
  • First patient dosed in Moderna collaboration (mRNA-4200) triggering a milestone payment.
  • R&D expenses rose to $71.1M (€62.4M) from $51.4M (€45.1M) YoY due to SUPRAME trial advancement.

Financial Impact

EPS beat of ~9.5% partially offset by revenue miss of ~17.5% vs consensus; net loss improved YoY by ~11%.

revenueeps

Risk Factors

  • Revenue miss and elevated R&D spending could pressure near-term sentiment.
  • Phase 3 SUPRAME trial success is binary; slower event accrual adds execution risk.
  • Pre-revenue biotech with no approved products; reliance on future trial readouts and regulatory approvals.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3346680

Track record

23 reports on IMTX

Performance horizon

8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
  3. Nov 10, 20266d ago 6-K Neutral 5/10 No price data
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
  5. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  6. Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  7. Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
  8. Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
  9. Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
  10. Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 18, 2026